Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at…
News
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Merger with Notable expected to close in late September or October, subject to VBL’s S-4…
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Merger with Notable expected to close in late September or October, subject to VBL’s S-4…
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot…
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot…
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
On track to begin a Phase 2a trial in the second half of 2023 with…
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
On track to begin a Phase 2a trial in the second half of 2023 with…
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in…
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in…
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage…
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage…
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma into Stage 2 becoming…
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma into Stage 2 becoming…
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Enrollment in PNT2002’s SPLASH trial is complete and topline data is expected in the fourth…
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Enrollment in PNT2002’s SPLASH trial is complete and topline data is expected in the fourth…
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early…
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early…
Kura Oncology Appoints Brian Powl as Chief Commercial Officer
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…